Cellvax Expands its Preclinical Service Offers by Moving to a New Laboratory Facility With an Access to Large Animals and a Number of New Technical Plat-Forms

PARIS, March 31, 2010 - Cellvax is a French service company which provides complete in
vitro & in vivo preclinical innovating services allowing to accelerate the
drug development process for unmet needs related with severe human diseases,
mainly in oncology field.

Cellvax was created in 2001 as a French SME by a motivated and
complementary team consisting of scientists and experts in these fields. By
offering its know-how and its capacity of innovation, Cellvax has
successfully accomplished numerous in vitro and in vivo studies for different
companies in Europe, Israel and in the world.

Cellvax's expertise is based on its know-how in in vitro
models, especially original in vivo models. These services can be offered to
all laboratories involving in anti-cancer drug development process. These
proposed services adapt to the validation and development of anti-cancer drug
candidates and are fully validated such as sub-cutaneous and orthotopic
tumors models in animals; in vitro and in vivo angiogenesis models; an
original "Nodule" system, tumor invasion tests, in vivo imaging,
bio-distribution, pharmacokinetics, toxicity, histological analysis,
biomarker studies, …

Cellvax is always ready to obey market evolution and to
satisfy its customers' specific needs all over the world. In order to enhance
its development and continuously satisfy its customers, Cellvax has recently
moved to a new laboratory facility, just on the border of Paris, inside
"Ecole Nationale Vétérinaire Alfort" (ENVA). The ENVA is one of the oldest
and largest veterinary universities in Europe, created in 1766, with an easy
access by subway. The ENVA is located on a large surface of 110 000 metres
squared, with more than one thousand people (Scientists, Professors,
technicians, students, …) working here. In this new facility, Cellvax is
able to provide to its customers a number of new services especially with
different species of animals (mice, rats, rabbits, dogs, minipigs, etc.),
spontaneous naturally-developed tumors, in vivo imaging plat-forms, MRI,
Scanner, Scintigraphy, histological analysis, biomarkers.

In summary, Cellvax is able to provide to its customers the
services not only in small animals, but also in large animals in a more
efficient way.

    Contact Cellvax: Ming Wei, Ph.D.

    President & CEO
    Ecole Nationale Vétérinaire Alfort
    Telephone: +33-(0)1-43-76-32-65; Mobile: +33-(0)6-71-43-47-51.
    E-mail: ming@cellvax-pharma.com

Web Site: www.cellvax-pharma.com/

Contact Cellvax: Ming Wei, Ph.D.: President & CEO, Ecole Nationale Vétérinaire Alfort, Telephone: +33-(0)1-43-76-32-65; Mobile: +33-(0)6-71-43-47-51, E-mail: ming at cellvax-pharma.com